What is Noble Financial’s Estimate for GLSI FY2025 Earnings?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Investment analysts at Noble Financial lowered their FY2025 EPS estimates for shares of Greenwich LifeSciences in a research note issued on Wednesday, December 10th. Noble Financial analyst R. Leboyer now expects that the company will post earnings of ($1.30) per share for the year, down from their prior forecast of ($1.25). Noble Financial currently has a “Outperform” rating and a $45.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30).

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Greenwich LifeSciences in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $42.00.

Greenwich LifeSciences Stock Down 4.8%

NASDAQ GLSI opened at $10.73 on Friday. The stock’s 50-day moving average price is $9.20 and its 200-day moving average price is $10.20. The company has a market capitalization of $148.61 million, a P/E ratio of -7.35 and a beta of 1.61. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $14.47.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently modified their holdings of GLSI. Police & Firemen s Retirement System of New Jersey purchased a new position in Greenwich LifeSciences during the second quarter valued at $25,000. Bank of America Corp DE boosted its holdings in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the last quarter. Rhumbline Advisers grew its position in shares of Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of Greenwich LifeSciences in the first quarter worth about $147,000. Finally, Strs Ohio purchased a new stake in shares of Greenwich LifeSciences in the first quarter worth about $177,000. Institutional investors own 4.16% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Snehal Patel acquired 10,600 shares of the business’s stock in a transaction on Friday, November 7th. The stock was acquired at an average cost of $8.43 per share, with a total value of $89,358.00. Following the acquisition, the chief executive officer directly owned 5,583,502 shares in the company, valued at $47,068,921.86. This represents a 0.19% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders purchased 17,500 shares of company stock valued at $149,158. Corporate insiders own 51.47% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.